Abiomed is dedicated to finding ways to treat heart failure so that patients and physicians with have the most advanced, most successful, and most beneficial technology available. Our products focus on acute heart failure, with products across the continuum of care to support physician and patient needs.

The IMPELLA devices are minimally invasive catheter pumps that can support the heart with up to 5.5 liters blood per minute. The pumps can be implanted percutaneously, via a cut-down, or in the OR.

The AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System provide temporary support for one or both sides of the natural heart in circumstances where the heart has failed but has the potential to recover.

The BVS 5000 is the most widely used advanced cardiac assist system in the world, installed in more than 700 leading medical centers worldwide. The AB5000 is ABIOMED's advanced technology offering, approved by the FDA in 2003. It is designed to provide improved patient mobility, comfort and ease of use and can be used either in the hospital or for transport of patients between hospitals.

The AbioCor is the world's first completely self-contained replacement heart. A product of three decades of research, development and testing, the AbioCor is central to ABIOMED's mission to make real the day when heart failure need not mean the end of life or the ability to enjoy life. Designed to fully sustain the body's circulatory system, the AbioCor is intended for end-stage heart failure patients whose other treatment options have been exhausted.

In 2001, ABIOMED made history when Mr. Robert Tools, a 58-year-old telephone company employee and teacher suffering from end stage heart failure was successfully implanted with the first AbioCor. The initial clinical trial is continuing with the aim of gaining approval to market the AbioCor to support patients with irreversible end-stage heart failure. The FDA approved the AbioCor for commercial approval under a Humanitarian Device Exemption (HDE) in September 2006.

ABIOMED is also working on the next generation implantable replacement heart, the AbioCor II. Incorporating technology both from ABIOMED and Penn State, the AbioCor II is smaller and is being designed with a goal of five year reliability.